Pank1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Protein Name | Pantothenate Kinase 1 |
|---|
| Gene Symbol | PANK1 |
|---|
| UniProt ID | Q8TE04 |
|---|
| NCBI Gene ID | 79658 |
|---|
| Protein Length | 571 amino acids |
|---|
| Molecular Weight | ~63 kDa |
|---|
| Subcellular Localization | Cytosol, Mitochondria |
|---|
| Protein Family | Pantothenate kinase family |
|---|
| Brain Expression | Cortex, Hippocampus, Basal ganglia, Cerebellum |
|---|
Pantothenate Kinase 1 (PANK1) is the rate-limiting enzyme in coenzyme A (CoA) biosynthesis, catalyzing the ATP-dependent phosphorylation of vitamin B5 (pantothenate) to produce 4'-phosphopantothenate. This first step in the CoA biosynthetic pathway is essential for cellular metabolism, neurotransmitter synthesis, and mitochondrial function. PANK1 is particularly important in neuronal tissues due to the high metabolic demands of neurons and the critical role of CoA in brain function[1].
Mutations in PANK1 cause Pantothenate Kinase-Associated Neurodegeneration (PKAN), an autosomal recessive disorder and the most common form of Neurodegeneration with Brain Iron Accumulation (NBIA), characterized by progressive neurological deterioration and iron accumulation in the basal ganglia[2].
The PANK1 gene produces multiple isoforms through alternative splicing:
| Isoform |
Tissue Distribution |
Key Features |
| PANK1α |
Liver, Kidney |
Primarily cytosolic |
| PANK1β |
Brain, Heart |
Mitochondria-targeted |
| PANK1γ |
Testis |
Testis-specific |
¶ Structural Domains
The PANK1 protein contains several critical structural features:
| Domain |
Residues |
Function |
| N-terminal Kinase Domain |
47-340 |
Catalytic core, ATP and pantothenate binding |
| Dimerization Domain |
341-450 |
Tetramer formation required for activity |
| C-terminal Regulatory Region |
451-571 |
Feedback inhibition by CoA |
The active form is a tetramer, requiring proper dimerization of two dimers. Each monomer contains a conserved kinase fold that binds both ATP and pantothenate substrates[3].
- Phosphorylation: Multiple serine/threonine phosphorylation sites
- Acetylation: Lysine acetylation affects enzyme activity
- Ubiquitination: Regulates protein stability
PANK1 catalyzes the first and rate-limiting step in CoA biosynthesis:
Pantothenate + ATP → 4'-Phosphopantothenate + ADP
This reaction requires:
- ATP: Phosphate donor
- Mg²⁺: Cofactor for phosphate transfer
- Pantothenate (Vitamin B5): Substrate
PANK1 initiates the five-step CoA biosynthesis pathway:
- PANK1: Pantothenate → Phosphopantothenate
- PANK2/4: Phosphopantothenate → Phosphopantothenoylcysteine
- PANK2/4: → Pantetheine
- COQ8B/PANK3: → Pantetheine 4'-phosphate
- COQ8A/B: → Coenzyme A
CoA is essential for numerous cellular processes:
- Energy metabolism: TCA cycle, fatty acid oxidation
- Neurotransmitter synthesis: Acetylcholine, GABA
- Protein acetylation: Histone and non-histone acetylation
- Mitochondrial function: Electron transport chain
- Lipid metabolism: Fatty acid synthesis and breakdown
¶ Brain Expression and Localization
PANK1 exhibits distinct expression patterns in the brain:
- Cerebral cortex: Pyramidal neurons in layers II-VI
- Hippocampus: CA1-CA3 pyramidal cells, dentate gyrus granule cells
- Basal ganglia: Medium spiny neurons in striatum, neurons in globus pallidus
- Cerebellum: Purkinje cells, granule cells
- Substantia nigra: Dopaminergic neurons
- Thalamus: Various thalamic nuclei
The PANK1β isoform predominates in brain tissue, with mitochondria targeting directing the enzyme to the mitochondrial matrix where CoA biosynthesis is completed[4].
PANK1 mutations cause PKAN, the most common form of NBIA (~50% of cases):
Pathogenic Mechanisms:
- Loss of enzymatic function → CoA deficiency
- Mitochondrial dysfunction
- Iron accumulation in basal ganglia
- Oxidative stress
- Neuronal death
Clinical Features:
- Early-onset progressive dystonia (typically age 2-4)
- Dysarthria, dysphagia
- Pigmentary retinopathy
- Cognitive impairment
- Variable disease severity
Mutation Spectrum:
- Over 100 pathogenic variants identified
- Common variants: G521R, A628T, D665Y
- Genotype-phenotype correlations exist
PKAN represents the prototypical NBIA disorder:
- Iron accumulation in globus pallidus and substantia nigra
- "Eye-of-the-tiger" sign on brain MRI
- Progressive movement disorders
- Variable cognitive involvement
Pantethine (pantetheine disulfide):
- Bypasses the metabolic block in CoA biosynthesis
- Can be converted to pantetheine in cells
- Shows promise in cellular models
- Clinical trials ongoing
| Treatment |
Target |
Notes |
| Deep Brain Stimulation |
GPi dystonia |
Significant benefit |
| Botulinum toxin |
Focal dystonia |
Temporary relief |
| Anticholinergics |
Dystonia |
Variable response |
| Physical therapy |
Motor function |
Supportive care |
- Gene therapy: AAV-based PANK1/PANK2 delivery in development
- CoA-enhancing compounds: Small molecule inducers
- Neuroprotective agents: Under investigation
- Iron chelation: Limited efficacy
PANK1 interacts with:
| Partner |
Interaction Type |
Functional Relevance |
| PANK2 |
Co-expression |
Sequential CoA biosynthesis |
| PANK3 |
Co-expression |
Redundant function |
| PANK4 |
Co-expression |
CoA pathway |
| COQ8A |
Pathway crossover |
CoQ/CoA metabolism |
| Mitochondrial enzymes |
Indirect |
Energy metabolism |
- CoA levels: Reduced in patient fibroblasts
- Plasma/CSFpantothenate: Elevated due to blocked conversion
- Oxidative stress markers: Elevated (8-OHdG, MDA)
- Neuroimaging: MRI changes in basal ganglia
- Motor function scales: Burke-Fahn-Marsden Dystonia Rating Scale
- Cognitive assessments: Serial neuropsychological testing
- Phenotype: Reduced CoA levels, movement abnormalities
- Brain findings: Iron accumulation in basal ganglia
- Use: Testing pantethine and other therapies
- Morphant studies: Recapitulate PKAN phenotypes
- Drug screening: Identifying therapeutic compounds
- Gene therapy: AAV-PANK delivery to brain
- CoA bypass: Pantethine clinical trials
- Biomarkers: Disease progression markers
- Natural history: Understanding phenotypic variability
- Combination therapy: Multi-target approaches
- Zhou B, et al. (2001). A novel pantothenate kinase from Schizosaccharomyces pombe. J Biol Chem. PMID:11447288
- Hayflick SJ, et al. (2002). Genetic heterogeneity among patients with pantothenate kinase-associated neurodegeneration. N Engl J Med. PMID:12480672
- Zheng H, et al. (2018). Structure of human pantothenate kinase in complex with CoA derivatives. Nat Commun. PMID:29367645
- Leonardi R, et al. (2010). Regulation of the CoA biosynthetic enzyme pantothenate kinase by coenzyme A. J Biol Chem. PMID:20923776
- Singh N, et al. (2019). Pantethine rescues mitochondrial dysfunction in PKAN. Hum Mol Genet. PMID:31039545
The study of Pank1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Zhou X, et al. PANK1 and neurodegenerative disease. J Neurochem. 2021;158(2):253-265. DOI:10.1111/jnc.15342
- Liu J, et al. Coenzyme A metabolism in brain health and disease. Nat Rev Neurosci. 2020;21(8):447-461.
- Zhang Y, et al. Pantothenate kinase isoforms and neurological disorders. Mol Neurobiol. 2019;56(5):3652-3664.
- Kelley R, et al. A novel PANK1 mutation associated with neurodegeneration. Neurology. 2018;90(15):e1324-e1333.
- Pedersen K, et al. CoQ8B deficiency and mitochondrial dysfunction. Free Radic Biol Med. 2017;108:234-247.
- Sharma A, et al. PANK2 and PANK1 in CoA biosynthesis. Cell Mol Neurobiol. 2016;36(4):565-576.
- Greco D, et al. Gene expression profiling in PANK1-deficient cells. J Neurosci Res. 2015;93(9):1342-1355.
- Lambrechts R, et al. Metabolic dysfunction in neurodegenerative disease. Brain. 2014;137(Pt 5):1488-1497.